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Children are patch-tested in the same manner as adults, 
but little has been done to establish whether positive or 
negative findings influence the course of skin symptoms. 
To uncover the course of skin symptoms and the impact 
of persistent eczema on life quality in paediatric patients 
referred for patch testing, a retrospective questionnaire 
was sent to children and adolescents referred for patch 
testing during a 9-year period. Persistent eczema at fol-
low-up was strongly associated to atopic dermatitis, but 
was not explained by gender, age, contact allergy or time 
span from patch testing to follow-up. Among patients 
without atopic dermatitis, 23.5% reported to suffer from 
chronic eczema. Persistent eczema increased the risk of 
severe impairment of life quality. Our findings indicate 
a significant risk of childhood eczema becoming chronic 
and affecting life quality considerably. Patch testing did 
not affect the course of eczema, highlighting the diffi-
culties of avoidance behaviour. Key words: patch testing; 
children; adolescents; allergic contact dermatitis; contact 
allergy; atopic dermatitis.
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Allergic contact dermatitis (CD) is a common derma-
tological disorder and often results in ongoing disease 
and disability (1, 2). Even young children may become 
sensitised and suffer from allergic CD (3). Early identi-
fication and subsequent avoidance of the contact allergen 
by the patient should reduce the duration and disability 
of the disease and its progression. However, studies on 
the outcome of patch testing in children with suspected 
allergic CD are limited (4) and little has been done to 
establish whether positive or negative findings influence 
the course of skin symptoms (5). 
It is well known that many skin diseases have a sig-
nificant impact on quality of life (QoL) (6). This has 
been demonstrated in children with atopic dermatitis 
(7) as well as in adult patients with allergic CD (1), but 
little attention has been paid to children and adolescents 
suffering from the latter. 
The aim of this study was to uncover the course of skin 
symptoms in paediatric patients referred for patch testing, 
and to evaluate the impact of skin symptoms on QoL.
METHODS
Patient selection
From 1 January 2003 to 31 December 2011 a total of 2,594 
patients aged 1–17 years were patch-tested in 12 dermatological 
clinics throughout Denmark (The Danish Group for Contact 
Dermatitis), which is estimated to cover about 1/5 of patients 
patch-tested in Denmark. All patients either suffered from 
recalcitrant eczema or had a suspected diagnosis of allergic 
CD. Characteristics according to the MOAHLFA index (Male, 
Occupational dermatitis, Atopic dermatitis, Hand dermatitis, 
Leg dermatitis, Face dermatitis) were registered by the derma-
tologist prior to patch testing. The diagnosis of atopic dermatitis 
was established according to the Hanifin and Rajka criteria (8).
Patch testing
The children were tested with either the European Baseline 
Series (allergens retrieved from either Chemotechnique Diag-
nostics, Malmö, Sweden, or from Almirall Hermal, Reinbek, 
Germany) or with TRUE test (SmartPractice Denmark, Hil-
leroed, Denmark) supplemented with the allergens from the 
European Baseline Series that are not included in the TRUE test. 
Patch tests were removed on day 2. Readings were performed 
according to The International Contact Dermatitis Research 
Group Guideline on minimum day 2 or day 4, and often also 
day 2 and day 7. Reactions designated either “1+”, “2+”, or 
“3+” were regarded as positive. 
Follow-up
Of the 2,594 patients in the database, 2,591 were registered in 
the Danish Civil Registration System, and 2,567 had a valid 
address in Denmark. Since 307 did not wish to be contacted 
for research purposes, the questionnaire-based follow-up was 
conducted on the remaining 2,260 patients in the spring of 2013. 
Questionnaire
The questionnaire designed for this follow-up study aimed to 
describe the skin status of the cohort and to uncover persisting 
skin symptoms. Since some of the patients were younger children, 
we made it optional for them to either answer the questionnaire 
themselves or with help from their parents. To investigate how 
well the outcome of the patch test was remembered by the patients 
and/or their parents, they were asked if they had contact allergy 
to metals, fragrances, preservatives, plants or rubber. To study the 
current skin status of the patients, they were asked “how often do 
you/your child have eczema?” with the response options “never”, 
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“all the time/every day”, “every week”, “1–3 times every month”, 
“4–6 times every year”, and “1–3 times every year”. To investigate 
the QoL of those with persisting skin symptoms, the Children’s 
Dermatology Life Quality Index (CLDQI) questionnaire (9) was 
used for patients aged 16 or younger. For patients aged 17 and 
above, the Dermatology Life Quality Index (DLQI) (10) ques-
tionnaire was used. The CDLQI and DLQI each consists of 10 
questions that focus on the effects of skin disease on activities of 
daily life during the preceding week. Since this was a follow-up 
study, the temporal parameter was expanded to the preceding year.
Definitions
To classify the severity of skin symptoms at follow-up and 
identify the patients that were severely affected, we defined the 
variables “persistent eczema” as eczema all the time/every day 
or at least once every week, “frequent eczema” as eczema 1–3 
times each month, and “rarely eczema” as episodes of eczema 
less than 6 times each year. 
The CDLQI/DLQI is calculated by summing the score for 
each question, which results in a maximum score of 30 and a 
minimum score of 0. The scoring and interpretation was done 
according to the authors’ instructions (9, 11). “Severely affected 
life quality” was defined as a CDLQI score ≥ 13 or DLQI score 
≥ 11 (“very large” or “extremely large” effect on patient’s life). 
Statistics
Characteristics of participants were compared using the χ2 
test. A binary logistic regression analysis was performed with 
“persistent eczema” as the dependent variable, and atopic der-
matitis, contact allergy, gender, age at patch testing (1–5 years, 
6–12 years, and 13–17 years) and follow-up time (2–4 years, 
5–7 years, 8–10 years) as independent, explanatory variables. 
Since atopic dermatitis was a major confounder, the logistic 
regression model was repeated, including only the patients wit-
hout atopic dermatitis. The χ2-test was used to compare groups 
and assess explanatory parameters of “severely affected life 
quality”. All results were expressed as odds ratios with 95% 
confidence intervals and employing a 5% significance level.
The data analysis was done using statistical software (Sta-
tistical Product and Service Solution package for Windows, 
Release 19, SPSS® Inc., Chicago, IL, USA).
RESULTS
In total, 1,039 questionnaires were returned after one 
reminder, giving a response rate of 46%. The demo-
graphic characteristics of the cohort and differences 
between the responders and non-responders are sum-
marised in Table I. Respondents were more likely to 
be female, younger than 20 years at follow-up, patch-
tested less than 5 years ago, and having a diagnosis of 
atopic dermatitis at the time of patch testing. 
The respondents were 3–17 years (mean 12.8 years) at 
the time of patch testing. Time to follow-up was between 
2 and 10 years (mean 5.2 years), and the current age of 
the respondents was 4–28 years (mean 17.7 years). More 
than two thirds of the respondents were girls (68.1% vs. 
32.9%), 48.6% (n = 505) had a diagnosis of atopic der-
matitis (AD) when patch-tested, and 25% (n = 260) had 
at least one positive patch test reaction. Among respon-
dents, there were no sex difference in the likelihood of 
having at least one positive patch test reaction, and the 
share that suffered from AD was the same in the 2 groups. 
Skin symptoms at follow-up
Of all respondents, 90.8% (n = 943) answered the ques-
tion regarding their current skin status. In this group, 
51.5% (n = 486) had a diagnosis of AD and 80.3% 
(n = 757) reported that they still suffer from eczema at 
least once every year. Persistent eczema at follow-up 
was reported by 31.1% (n = 293) and was not sur-
prisingly associated with having AD at the time of patch 
testing (OR 2.10, CI 1.59–2.78, p < 0.01), but not with 
having contact allergy (OR 0.91, CI 0.66–1.25, p = 0.55) 
or having 2 or more allergies (OR 0.65, CI 0.40–1.04, 
p = 0.07). No difference between genders or across age 
groups was observed, and the risk of having persistent 
eczema at follow-up was the same regardless of the time 
from patch testing to follow-up (Table II). The same 
applied when the analyses were stratified by AD (Table 
SI1). Among respondents without AD, 70.4% (n = 342) 
reported to suffer from eczema at least once every year 
and 23.5% (n = 114) suffered from persistent eczema.
Metals, fragrance and rubber chemicals were the 
most frequent sensitisers, but no specific group of al-
lergens was associated with having continuous eczema 
at follow-up. 
Of the 260 patients who were sensitized to at least one 
allergen, 66.5% (n = 173) answered the question regar-
Table I. Demographic characteristics of responders versus non-
responders
All patients 
2,260 (100) 
n (%)
Responders 
1,039 (46) 
n (%)
Non-responders 
1,221 (54) 
n (%) OR (95% CI)
Age, years
< 10 124 (5.5) 84 (8.1) 40 (3.3) 2.60 (1.77–3.82)***
11–15 394 (17.4) 205 (19.7) 189 (15.5) 1.34 (1.08–1.67)**
16–20 990 (43.8) 479 (46.1) 511 (41.9) 1.19 (1.01–1.40)*
> 21 752 (33.3) 271 (26.1) 481 (39.4) 0.54 (0.45–0.65)*
Gender
Male 776 (34.3) 331 (31.9) 445 (36.4) 0.82 (0.68–0.97)*
Female 1,484 (65.7) 708 (68.1) 776 (63.6)
Atopic dermatitis
Yes 1,011 (44.7) 505 (48.6) 506 (41.4) 1.34 (1.13–1.58)**
No 1,249 (55.3) 534 (51.4) 715 (58.6)
Contact allergy
Yes 556 (25.0) 260 (25.0) 306 (25.1) 1.00 (0.83–1.21)
No 1,694 (75.0) 779 (75.0) 915 (74.9)
Follow-up, years
2–4 937 (41.5) 493 (47.4) 444 (36.4) 1.58 (1.34–1.87)***
5–7 691 (30.6) 302 (29.1) 389 (31.9) 0.88 (0.73–1.05)
8–10 632 (28.0) 244 (23.5) 388 (31.8) 0.66 (0.55–0.80)***
*p < 0.05, **p < 0.005, ***p < 0.001.
Odds ratio (OR) found by χ2 testing across subgroups.
CI: confidence interval.
1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-1911
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ding the outcome of the patch test and 55.5% (n = 96) of 
these were able to correctly identify the group of allergens 
to which the specific allergen belonged. The ability to 
correctly recall the allergen group decreased with time. 
There was no association between having persistent ec-
zema at follow-up and being unable to identify the correct 
group of allergens (OR 0.91, CI 0.46–1.81, p = 0.79). 
Life quality
Among those who suffered from eczema at least once 
a year, 76.1% (n = 576) answered the CDLQI or DLQI 
depending on age. The mean CDLQI score was 6.38 
(range 0–23) vs. mean DLQI score of 6.81 (range 
0–29). The CDLQI/DLQI score was correlated to the 
severity of the eczema and patients with AD were more 
affected than patients without this diagnosis in both 
groups (Fig. S11).
Persistent eczema was a strong and significant risk 
factor for having severely impaired life quality in both 
patients ≤ 16 years and in patients ≥ 17 years. However, 
the majority of patients had CDLQI/DLQI scores cor-
responding to a small or moderate impact on life quality. 
In the group of respondents ≤ 16 years, young child-
ren were more likely to have severely affected life 
quality at follow-up (Table III). This was associated to 
AD whereas no gender difference was observed. The 
association to AD did not reach statistical significance 
at a 5% level, which is likely due to small sample sizes. 
Because of the strong link between having AD and per-
sistent eczema at follow-up, analyses were stratified by 
AD. Persistent eczema was still the strongest predictor 
of severely affected life quality. The pattern was similar 
in patients ≥ 17 years. In this age group, the role of AD 
was less pronounced. As in the youngest age group, the 
risk of having severely affected life quality increased 
with the severity of eczema, and this pattern persisted 
when stratified by AD. There was no age difference 
within this group but we did observe a significant gender 
difference, with the life quality of females being more 
affected than that of males (Table IV). 
DISCUSSION
To our knowledge, this is the first long-term follow-
up study exploring the course of skin symptoms in 
children referred for patch testing. 
A significant share of the respondents 
still suffered from flare-ups of eczema at 
follow-up and many suffered from per-
sistent eczema. AD was the single most 
important risk factor for having persistent 
eczema at follow-up, but even among the 
children and adolescents without diagnosed 
AD the share of patients who suffered from 
persistent eczema was substantial. At base-
line, all patients were suspected of having 
allergic CD either as a complicating factor 
or as the main cause of disease. However, 
a positive patch test result was not found to 
affect the prognosis of eczema. There are 
several possible explanations for this. First 
of all, the accuracy of patch testing is multi-
factorial and depends on the competence of 
the tester (12). A satisfactory result requires 
careful consideration of exposures and se-
lection of appropriate allergens for the patch 
testing. Further, the benefits of patch testing 
Table II. Logistic regression analysis with the outcome ”persistent 
eczema” and different explanatory variables
Explanatory 
variables
Persistent eczemaa 
% (n/ntotal)
Crude ORb 
(95% CI)
Adjusted ORb 
(95% CI)
Gender
Male 30.9 (94/304) 1 (ref) 1 (ref)
Female 31.1 (199/639) 1.01 (0.75–1.33) 1.01 (0.74–1.36)
Age, years
< 10 34.6 (27/78) 1 (ref) 1 (ref)
11–15 27.6 (51/185) 0.72 (0.41–1.27) 0.86 (0.48–1.53)
16–20 31.5 (138/438) 0.87 (0.52–1.44) 1.02 (0.60–1.72)
> 21 31.8 (77/242) 0.88 (0.51–1.51) 1.22 (0.64–2.32)
Atopic dermatitis
No 23.5 (114/486) 1 (ref) 1 (ref)
Yes 39.2 (179/457) 2.10 (1.59–2.78) 2.05 (1.54–2.72)*
Contact allergyc
No 31.6 (220/696) 1 (ref) 1 (ref)
Yes 29.6 (73/247) 0.91 (0.66–1.25) 0.98 (0.71–1.35)
Follow-up, years
2–4 33.8 (152/450) 1 (ref) 1 (ref)
5–7 28.2 (78/277) 0.77 (0.55–1.07) 0.74 (0.52–1.06)
8–10 29.2 (63/216) 0.81 (0.57–1.15) 0.72 (0.45–1.13)
*p < 0.05.
an = 293. bAdjusted for all explanatory variables. cPositive patch test reaction 
to at least one allergen.
OR: odds ratio; CI: confidence interval. 
Table III. Predictors of having severely affected life quality. Patients ≤ 16 years
Explanatory 
variables
All patients Without atopic dermatitis
CDLQI severely 
affected (n = 124) 
% (n/ntotal)
Crude ORa 
(95% CI)
CDLQI severely 
affected (n = 54) 
% (n/ntotal)
Crude ORa 
(95% CI)
Gender
Male 15.8 (9/57) 1 (ref) 12.0 (3/25) 1 (ref)
Female 16.4 (11/67) 1.05 (0.40–2.74) 6.9 (2/29) 0.54 (0.08–3.55)
Age, years
≤10 24.4 (12/49) 1 (ref) 12.5 (2/16) 1 (ref)
11–16 10.76 (8/75) 0.37 (0.14–0.98)* 7.9 (3/38) 0.6 (0.09–3.99)
Atopic dermatitis
No 9.3 (5/54) 1 (ref)
Yes 21.4 (15/70) 2.67 (0.91–7.90)**
Contact allergyb
No 16.0 (15/94) 1 (ref) 9.8 (4/41) 1 (ref)
Yes 16.7 (5/30) 1.05 (0.35–3.19) 7.7 (1/13) 0.77 (0.08–7.58)
Persistent eczema
No 7.1 (6/84) 1 (ref) 4.8 (2/42) 1 (ref)
Yes 35.0 (14/40) 7.00 (2.44–20.09)* 25.0 (3/12) 6.67 (0.97–45.92)*
aOdds ratios (OR) calculated by χ2 testing across subgroups.
bAt least one positive patch test reaction.
*p < 0.05, **p = 0.07.
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depends on the information given regarding avoidance 
of allergens (13, 14), and most importantly the patient’s 
ability to recall the results of the patch testing (12) and 
subsequently avoid the contact allergen.
Avoidance of allergens can be a major challenge, as 
demonstrated by Lewis et al. (15). Among 43 patients 
with allergic CD, only half were able to avoid the al-
lergens concerned. Accordingly, our results suggest that 
the patients who were diagnosed with allergic CD may 
have had difficulties in adopting suitable avoidance 
behaviour. 
Another aspect of avoidance behaviour is the patient’s 
ability to recall the results of the patch test. Jamil et al. 
(12) showed that patients’ ability to recall the diagnosed 
allergen decreased over time and at 10-year follow-up 
only 17% percent were able to recall the correct al-
lergen. In our study only 55.5% were able to correctly 
identify the group of allergens. We hypothesised that 
being unable to remember the outcome of the patch 
test was correlated to having persistent skin symptoms 
at follow-up. However, we were not able to show that 
this was the case. It could be argued that our question 
regarding the outcome of the patch test was too vague, 
i.e. asking the respondents to name the allergen to 
which they had a positive reaction would have been 
more accurate. It is also possible that the challenge of 
avoidance behaviour biased the result, i.e. those who 
correctly recalled the outcome, were unable to avoid 
the specific allergen. In any event, our results indicate 
that there is a need of reminding patients of any positive 
results, and this is likely to be even more pronounced 
if the patch testing is carried out at an early age, where 
information is primarily given to the parents. 
We cannot reject the possibility that AD in some cases 
were misclassified, which would help explain the large 
share with persistent skin symptoms. However, it is well 
known that CD often results in ongoing 
disease (2), and it could also be that a 
share of the children and adolescents 
with skin symptoms not explained by 
AD or contact allergy, represent a group 
suffering from irritant CD, indicating 
that this is a significant problem among 
children. Other differential diagnoses 
are nummular eczema, seborroheic 
dermatitis, and solar dermatitis. 
Finally, it is possible that some of the 
patients developed new contact allergies 
in the time from primary patch testing 
to follow up. Mortz et al. (16) recently 
showed that the incidence rate of contact 
allergy increased from adolescence to 
adulthood. 
As expected, life quality and disease 
severity were correlated. Life quality 
was severely affected in a significant 
share of patients with persistent eczema. 
However, in an even larger proportion of patients, per-
sistent eczema only had a small to moderate effect on 
life quality. This finding may help to explain why so 
many suffered from persistent eczema, i.e. the impact 
on life quality is not perceived as significant enough to 
offset the efforts of implementing avoidance strategies 
in daily life.
Children aged 3–10 years were more likely to have 
severely affected life quality than children aged 11–16, 
which was explained by the interaction effect of AD 
and persistent eczema. Because of the small size of the 
subgroups among respondents of the CDLQI, we were 
unable to make strong conclusions for children ≤ 16. 
Statistical analyses with adjustment for gender, age, 
AD, and any interaction effects between explanatory 
variables would have been ideal. Unfortunately our 
sample size did not allow this. 
Several studies have explored the impact of different 
skin disorders on life quality in children and adolescents 
and most concern AD. Like Gånemo et al. (17) we were 
unable to show any gender difference in children ≤ 16 
year. We demonstrated a convincing gender difference 
in our population of patients ≥ 17 years with ongoing 
eczema regardless of the natural history. Similar to our 
results, Ballardini et al. (18) found pre-adolescent girls 
with mild eczema to have greater impairment of self-
perceived health compared to boys. Our finding may 
well reflect that adolescent girls and young women are 
more concerned about appearance than males of the 
same age. 
Despite the relatively low response rate of 46%, we 
did achieve a large sample size of 1039 subjects. The 
low response rate may to some extent be explained by 
the large span in follow-up time, i.e. patients may be 
less likely to respond to questionnaires regarding events 
that happened several years ago. 
Table IV. Predictors of having severely affected life quality. Patients ≥ 17 years
Explanatory 
variables
All patients Without atopic dermatitis
DLQI severely 
affected (n = 452) 
% (n/ntotal)
Crude ORa 
(95% CI)
DLQI severely 
affected (n = 198) 
% (n/ntotal) Crude OR
a (95% CI)
Gender
Male 9.5 (11/116) 1 (ref) 6.0 (3/50) 1 (ref)
Female 25.3 (85/336) 3.23 (1.66–6.31)** 22.3 (33/148) 4.50 (1.32–15.38)*
Age, years
17–21 21.9 (69/315) 1 (ref) 19.1 (26/136) 1 (ref)
≥22 19.7 (27/137) 0.88 (0.53–1.44) 16.1 (10/62) 0.81 (0.36–1.81)
Atopic dermatitis
No 18.2 (36/198) 1 (ref)
Yes 23.6 (60/254) 1.39 (0.88–2.21)
Contact allergyb
No 21.3 (72/338) 1 (ref) 18.4 (4/41) 1 (ref)
Yes 21.1 (24/114) 0.99 (0.59–1.66) 17.7 (11/62) 0.96 (0.44–2.10)
Persistent eczema
No 11.8 (32/271) 1 (ref) 7.2 (9/125) 1 (ref)
Yes 35.4 (64/181) 4.09 (2.53–6.59)** 37.0 (27/73) 7.57 (3.31–17.32)**
aOdds ratios (OR) calculated by χ2 testing across subgroups.
bAt least one positive patch test reaction.
*p < 0.05, **p < 0.001.
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There was an overrepresentation of female respon-
dents. The unequal gender distribution was, however, 
to some degree expected, as two thirds of the patients 
in our original data set was female and accordingly, 
several studies have shown that there is a female pre-
dominance among patients referred for patch testing 
(12). In addition, it has previously been demonstrated 
that young men are more likely to be non-responders 
than responders (19), and that women are more likely 
to return a mailed questionnaire (1). Stratified data 
analyses should eliminate any confounding. Another 
possible limitation is the fact that patients who suffer 
from eczema may be more likely to participate in ques-
tionnaire surveys concerning skin disease and further, 
retrospective questionnaire studies imply the inevitable 
limitation of recall bias. As regards to the assessment 
of continuous eczema, this was based on the patient’s 
information, and one could argue that a clinical assess-
ment would have been more accurate. 
Our findings indicate a significant risk of childhood 
eczema becoming chronic and affecting life quality 
considerably. As expected persistent eczema was stron-
gly associated to AD, but was not explained by gender, 
age, contact allergy or time span from patch testing to 
follow-up. Persistent eczema at follow-up increased 
the risk of severe impairment of life quality and this 
was especially pronounced in females ≥ 17 years. Patch 
testing did not affect the course of eczema, indicating 
that it can be extremely difficult to avoid the responsible 
allergens and further, patients may forget the patch 
test outcome. Children with skin symptoms should be 
carefully treated and guided, in order to minimise the 
disease burden and avoid chronicity and future socio-
economic consequences. We recommend providing 
each patient with a personal allergy information card.
The subject of this study is largely unexplored and 
there is a need of further elucidation of the area. Future 
studies should include clinical follow-up. It would also 
be of interest to repeat the patch test in order to deter-
mine if any new allergies have evolved. 
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